Astegolimab (MSTT 1041A; RG 6149) is a human IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research[1].
[1]. Steven G Kelsen, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-798.
















